Table 2.
Pooled results of survival and response rate in the A + T and TKI alone groups.
| Endpoints | Study numbers | A + T vs. TKI alone | HR/RR (95% CI) | P value |
|---|---|---|---|---|
| PFS | Median (95% CI), months | HR (95% CI) | ||
| PFS (INV) (overall) | 6 | 17.9 (16.3–19.5) vs. 11.9 (11.1–12.8) | 0.596 (0.516–0.689) | <0.01 |
| PFS (IRC) (overall) | 2 | 17.3 (15.3–19.2) vs. 11.2 (10.0–12.4) | 0.612 (0.506–0.740) | <0.01 |
| PFS in EGFR 19del | 4 | 18.4 (16.5–20.3) vs. 12.21 (11.0–13.4) | 0.611 (0.551–0.677) | <0.01 |
| PFS in EGFR L858R | 4 | 18.0 (15.5–20.4) vs. 10.76 (9.4–12.1) | 0.580 (0.468–0.718) | <0.01 |
| PFS in BM | 2 | 12.7 (9.7–NR) vs. 11.2 (8.8–14.7) | 0.529 (0.364–0.770) | 0.001 |
| PFS in no-BM | 2 | 18 (15.4–NR) vs. 15.1 (11.1–16.1) | 0.606 (0.462–0.797) | <0.01 |
| PFS in ECOG PS 0 | 3 | NR | 0.548 (0.417–0.721) | <0.01 |
| PFS in ECOG PS 1 | 3 | NR | 0.646 (0.507–0.786) | <0.01 |
| PFS2 (overall) | 2 | NR | 0.756 (0.612–0.934) | 0.010 |
| PFS in male | 4 | NR | 0.553 (0.433-0.706) | 0.003 |
| PFS in female | 5 | NR | 0.621 (0.519-0.742) | <0.01 |
| PFS in stage IIIB | 2 | NR | 0.393 (0.125-1.234) | 0.110 |
| PFS in stage IV | 3 | NR | 0.600 (0.505-0.713) | <0.01 |
| PFS in recurrence | 3 | NR | 0.440 (0.239-0.811) | 0.008 |
| PFS in never-smoker | 2 | NR | 0.645 (0.495-0.840) | 0.001 |
| OS | Median (95% CI), months | HR (95% CI) | P value | |
| OS (overall) | 4 | 46.1 vs. 47.4 | 0.933 (0.743–1.172) | 0.551 |
| OS in EGFR 19del | 3 | 46.6 vs. NC | 0.736 (0.352–1.539) | 0.416 |
| OS in EGFR L858R | 2 | 48.0 vs. 39.7 | 0.808 (0.543–1.204) | 0.295 |
| OSR | % (95% CI) | RR (95% CI) | P value | |
| 1-year OSR (overall) | 3 | 93.4% (90.6–96.2%) vs. 93.4% (90.7–96.2%) | 1.068 (0.607–1.880) | 0.818 |
| 2-year OSR (overall) | 2 | 79.2% (69.9–88.5%) vs. 78.3% (73.6–82.9%) | 0.876 (0.641–1.196) | 0.404 |
| ORR | % (95% CI) | RR (95% CI) | P value | |
| ORR (overall) | 6 | 77.3% (74–80.5%) vs. 74.4% (71–77.8%) | 0.884 (0.769–1.106) | 0.083 |
| ORR in EGFR 19del | 2 | 76.9% (70.7–80%) vs. 67.2% (60.2–74.1%) | 0.774 (0.641–0.936) | 0.008 |
| ORR in EGFR L858R | 2 | 67.9% (60.6–75.3%) vs. 64.9% (57.6–72.3%) | 0.937 (0.759–1.104) | 0.435 |
TKI: tyrosine kinase inhibitor; A + T: angiogenic inhibitors combined with TKI; 19del: exon 19 deletion; PFS: progression-free survival; PFS2: time from randomization to second disease progression or death from any cause; OS: overall survival; OSR: OS rate; ORR: objective response rate; DCR: disease control rate; NR; not reported; NC: not calculated; ECOG: Eastern Cooperative Oncology Group; PS: performance status; BM; INV: investigator-assessed; IRC: independent review committee-assessed; HR: Hazard ratios; RR: Relative risk ratios; 95% CI: 95% confidence intervals.